Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$72.60

0.075 (0.10%)

09:20
08/09/18
08/09
09:20
08/09/18
09:20

Reata Pharmaceuticals price target raised to $116 form $64 at Leerink

Leerink analyst Joseph Schwartz raised his price target for Reata Pharmaceuticals to $116 from $64 as an eventful Q2 sets up an "exciting" playout of catalysts over the next 18 mos. The analyst is more optimistic on the potential revenue streams from the company's rare renal disease franchise and has a higher conviction regarding their autosomal dominant polycystic kidney disease program. Schwartz reiterates an Outperform rating on the shares.

RETA Reata Pharmaceuticals
$72.60

0.075 (0.10%)

07/23/18
SBSH
07/23/18
NO CHANGE
Target $95
SBSH
Buy
Reata Pharmaceuticals price target raised to $95 from $76 at Citi
07/24/18
SBSH
07/24/18
NO CHANGE
Target $95
SBSH
Buy
Citi elevates Reata to top pick, boosts target to $95
Citi analyst Yigal Nochomovitz yesterday afternoon raised his price target for Reata Pharmaceuticals to $95 from $76 following data from the Phase 2 studies of bardoxolone methyl in patients with chronic kidney disease. The most anticipated catalyst for Reata in 2018 has read out with "resoundingly" positive data on the "challenging endpoint" of retained estimated glomerular filtration rate benefit in Alport Syndrome, Nochomovitz told investors yesterday in a research note titled "If You Are Not On B(o)ard Already, Now is the Time! Target to $95/shr." The analyst sees the Phase 3 Cardinal data readout in Alport in the second half of 2019 as "very" likely to work. He elevated Reata to his top pick and kept a Buy rating on the shares.
07/24/18
BARD
07/24/18
NO CHANGE
Target $92
BARD
Outperform
Reata Pharmaceuticals price target raised to $92 from $47 at Baird
Baird analyst Brian Skorney raised his price target on Reata Pharmaceuticals to $92 from $47 based on increased confidence in the probability of success in Alport and adding in ADPKD. He sees the bardoxolone profile as wide open for adoption in a variety of settings and sees the successful demonstration of efficacy as setting up the drug as a blockbuster. Skorney reiterated his Outperform rating on Reata Pharmaceuticals shares.
07/25/18
SBSH
07/25/18
NO CHANGE
Target $185
SBSH
Buy
Citi boosts Reata target to $185 from $95, adds to Focus List
Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $185 from $95 and added the stock to his firm's US Focus List. The shares closed yesterday up 40c to $76.95. The analyst also elevated Reata to the Top Pick in his SMID Biotech coverage space. The analyst added among rare nephropathies into his model following the company's "exceptional data" reported early this week in Alport syndrome. He now has "solid confidence" for bardoxolone methyl in other rare nephropathies. Autosomal dominant polycystic kidney disease is the most substantial market among the rare nephropathies in the analyst's model. Nochomovitz keeps a Buy rating on Reata.

TODAY'S FREE FLY STORIES

TEVA

Teva

$21.53

0.34 (1.60%)

, MYL

Mylan

$32.58

-0.45 (-1.36%)

10:25
10/18/18
10/18
10:25
10/18/18
10:25
Recommendations
Teva, Mylan, Amneal Pharmaceuticals, Novartis analyst commentary  »

Sandoz results…

TEVA

Teva

$21.53

0.34 (1.60%)

MYL

Mylan

$32.58

-0.45 (-1.36%)

AMRX

Amneal Pharmaceuticals

$18.66

0.17 (0.92%)

NVS

Novartis

$86.38

1.04 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 28

    Feb

ETP

Energy Transfer Partners

$21.75

-0.055 (-0.25%)

, ETE

Energy Transfer Equity

$17.00

-0.05 (-0.29%)

10:25
10/18/18
10/18
10:25
10/18/18
10:25
Conference/Events
Energy Transfer Partners to host special shareholder meeting »

Special shareholder…

ETP

Energy Transfer Partners

$21.75

-0.055 (-0.25%)

ETE

Energy Transfer Equity

$17.00

-0.05 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AAPL

Apple

$218.70

-2.5 (-1.13%)

10:21
10/18/18
10/18
10:21
10/18/18
10:21
Periodicals
EU won't pursue action against Ireland over Apple tax bill, Independent says »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAS

PhaseBio

$0.00

(0.00%)

10:21
10/18/18
10/18
10:21
10/18/18
10:21
Syndicate
PhaseBio opens at $5.00, IPO priced at $5.00 »

Citi, Cowen and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GE

General Electric

$12.21

0.015 (0.12%)

10:20
10/18/18
10/18
10:20
10/18/18
10:20
Options
Earnings hedge in GE »

Earnings hedge in GE. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
U.S. leading index rose 0.5% to 111.8 in September »

U.S. leading index rose…

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
Today's U.S. reports »

Today's U.S. reports…

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
Treasury Action: yields are loitering near highs »

Treasury Action: yields…

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
FX Action: The dollar »

FX Action: The dollar was…

LGND

Ligand

$207.27

4.52 (2.23%)

, NVS

Novartis

$86.49

1.15 (1.35%)

10:18
10/18/18
10/18
10:18
10/18/18
10:18
Recommendations
Ligand, Novartis analyst commentary  »

Ligand current valuation…

LGND

Ligand

$207.27

4.52 (2.23%)

NVS

Novartis

$86.49

1.15 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 06

    Nov

  • 07

    Nov

PTE

PolarityTE

$13.78

-0.81 (-5.55%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Hot Stocks
Breaking Hot Stocks news story on PolarityTE »

PolarityTE trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$230.34

-4.3 (-1.83%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Downgrade
Thermo Fisher rating change  »

Follow-up: Thermo Fisher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

HAL

Halliburton

$38.78

-0.78 (-1.97%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Downgrade
Halliburton rating change  »

Follow-up: Halliburton…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$9.23

-0.39 (-4.05%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Downgrade
Superior Energy rating change  »

Follow-up:Superior Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/18/18
10/18
10:16
10/18/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$13.78

-0.81 (-5.55%)

10:16
10/18/18
10/18
10:16
10/18/18
10:16
Hot Stocks
PolarityTE jumps 2% to $14.94 after Citron calls shares 'a zero' »

In a new research report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$71.72

-6.53 (-8.35%)

10:15
10/18/18
10/18
10:15
10/18/18
10:15
Recommendations
Activision Blizzard analyst commentary  »

Activision's CoD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
10/18/18
10/18
10:15
10/18/18
10:15
General news
Breaking General news story  »

Week of 10/12 EIA Natural…

PTE

PolarityTE

$13.44

-1.15 (-7.88%)

10:12
10/18/18
10/18
10:12
10/18/18
10:12
Hot Stocks
Breaking Hot Stocks news story on PolarityTE »

PolarityTE trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$13.44

-1.15 (-7.88%)

10:10
10/18/18
10/18
10:10
10/18/18
10:10
Periodicals
Breaking Periodicals news story on PolarityTE »

Citron calls PolarityTE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRPN

Groupon

$3.57

(0.00%)

10:10
10/18/18
10/18
10:10
10/18/18
10:10
Options
Upside call buyers in Groupon »

Upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.12

-0.33 (-0.61%)

10:07
10/18/18
10/18
10:07
10/18/18
10:07
Periodicals
Elizabeth Warren calls on the Fed to demand Wells Fargo fire CEO, CNBC says »

Senator Elizabeth Warren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

SNES

SenesTech

$0.78

0.0499 (6.82%)

10:06
10/18/18
10/18
10:06
10/18/18
10:06
Hot Stocks
SenesTech jumps after EPA amends label for ContraPest »

The jump in shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

MSC

Studio City

$0.00

(0.00%)

10:05
10/18/18
10/18
10:05
10/18/18
10:05
Syndicate
Studio City opens at $16.50, IPO priced at $12.50 »

Deutsche Bank, Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.